GlassScriptPhysician profile
Christopher M Stroud
NPI 1831431147
$19,188.42
in general payments reported to CMS, 2019-2025
40 companies · $4,288 in 2025
The $4,288 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $1,051 · 2021: $1,418 · 2022: $2,894 · 2023: $4,042 · 2024: $3,706 · 2025: $4,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,603.47 |
| Education | $433.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,203.43 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Lilly USA, LLC | $1,731.09 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $1,677.43 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,641.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,619.33 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,505.14 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Amgen INC. | $1,061.35 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $780.58 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $719.10 | 2023-2025 | Zoryve |
| Incyte Corporation | $702.73 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $552.02 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $535.83 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $483.83 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Mayne Pharma Commercial LLC | $461.17 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $345.94 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.